Anita D'Souza, MD

Associate Professor

view physician profile

Locations

Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Hindi

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Anita D’Souza, MD, MS completed medical school in Goa Medical College, India where she graduated at the top of her class and was voted Best Medical Graduate. She completed her Hematology and Medical Oncology fellowship at the Mayo Clinic, Minnesota.

Research Interests

Dr. D'Souza's clinical and research work is focused on plasma cell cancers (e.g. multiple myeloma, AL amyloidosis, POEMS syndrome, Waldenstrom Macroglobulinemia) and the use of hematopoietic cell transplantation to treat these diseases. She serves as a scientific director of the Plasma Cell Disorders and Adult Solid Tumors working committee in the Center for International Blood and Marrow Transplant Research (CIBMTR). She is principal investigator on clinical trials in amyloidosis and multiple myeloma. She is a recipient of the 2016 KL2 Career Development Award from the Clinical and Translational Science Institute. Dr. D’Souza is board certified in Internal Medicine, Hematology and Medical Oncology.

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.

(Munshi PN, Vesole DH, St Martin A, Davila O, Kumar S, Qazilbash M, Shah N, Hari PN, D'Souza A.) Cancer. 2021 Aug 10 PMID: 34374445 08/11/2021
What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma.

(D'Souza A, Lonial S.) J Clin Oncol. 2021 Aug 01;39(22):2423-2425 PMID: 34111942 06/12/2021
Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study.

(D'Souza A, Myers J, Cusatis R, Dispenzieri A, Finkel M, Panepinto J, Flynn KE.) Qual Life Res. 2021 Jul 13 PMID: 34255276 SCOPUS ID: 2-s2.0-85110447746 07/14/2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.

(Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A.) Leukemia. 2021 Jul;35(7):2141 PMID: 34091601 SCOPUS ID: 2-s2.0-85107532822 06/07/2021
Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults.

(Mishra A, Preussler JM, Bhatt VR, Bredeson C, Chhabra S, D'Souza A, Dahi PB, Hacker ED, Gowda L, Hashmi SK, Howard DS, Jakubowski A, Jayani R, Koll T, Lin RJ, Olin RL, Popat UR, Rodriguez C, Rosko A, Sabloff M, Sorror ML, Sung AD, Ustun C, Wood WA, Burns L, Artz A.) Transplant Cell Ther. 2021 07;27(7):617.e1-617.e7 PMID: 33836312 PMCID: PMC8254775 SCOPUS ID: 2-s2.0-85106248005 04/10/2021
Correlates and Outcomes of Early Acute Kidney Injury after Hematopoietic Cell Transplantation.

(Bhasin B, Ber Ce P, Szabo A, Chhabra S, D'Souza A.) Am J Med Sci. 2021 07;362(1):72-77 PMID: 33812909 SCOPUS ID: 2-s2.0-85105320844 04/05/2021
Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation.

(Mohan M, Hari P, Szabo A, Dhakal B, Chhabra S, D'Souza A.) Leuk Res. 2021 Jun 23;109:106648 PMID: 34182226 SCOPUS ID: 2-s2.0-85109506946 06/29/2021
Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

(Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M.) Clin Lymphoma Myeloma Leuk. 2021 Jun 18 PMID: 34257042 SCOPUS ID: 2-s2.0-85110347842 07/15/2021
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.

(Usmani SZ, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG.) Leukemia. 2021 May 28 PMID: 34050260 05/30/2021
Racial disparities in patients diagnosed with light chain (AL) amyloidosis.

(D'Souza A, Pezzin L, Laud P, Singh A.) Blood Cancer J. 2021 Apr 10;11(4):72 PMID: 33839739 PMCID: PMC8036230 SCOPUS ID: 2-s2.0-85104136315 04/12/2021
Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

(Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S.) Front Immunol. 2021;12:667054 PMID: 34149703 PMCID: PMC8206561 SCOPUS ID: 2-s2.0-85108140164 06/22/2021